Table 1.
SLE patient characteristics.
| Subject | Age at onset (yr) | Age at draw (yr) | Gender | SLEDAI | Kidney involvement | Prednisonea (mg/kg/day) | Other immunomodulatory medications* |
|---|---|---|---|---|---|---|---|
| jSLE033 | 14 | 16.3 | F | 22 | Yes | 0.19 | HCQ, Dipyridamole |
| jSLE040 | 7 | 13 | F | 18 | Yes | 0.36 | HCG, MMF, Dapsone, CyC, Abatacept |
| jSLE044 | 17 | 19.6 | F | 0 | No | 0.08 | HCQ, MMF |
| jSLE049 | 12 | 13.7 | F | 2 | No | 0.32 | HCQ |
| jSLE053 | 11 | 13.9 | F | 4 | No | None | HCQ |
| jSLE070 | 16 | 15.9 | F | 8 | Yes | 1.9 | HCQ, MMF |
| jSLE078 | 12 | 17.2 | F | 0 | Yes | None | HCQ, AZT, Dapsone |
| jSLE085 | 15 | 14.9 | F | 12 | No | None | None |
| jSLE086a | 11 | 12.7 | F | 6 | No | 0.73 | HCQ, MMF |
| jSLE086b | 13.7 | 0 | No | None | HCQ, MMF | ||
| jSLE087 | 15 | 16.5 | F | 2 | Yes | 0.11 | HCQ, AZT, Mesalamine |
| jSLE090 | 15 | 18.2 | F | 4 | Yes | None | None |
| jSLE101a | 16 | 16.5 | F | 22 | Yes | 1.23 | HCQ |
| jSLE101b | 17.6 | 8 | Yes | 0.1 | HCQ, MMF | ||
| jSLE105 | 15 | 16.3 | F | 7 | No | None | HCQ, MMF |
| jSLE107 | 14 | 17.4 | F | 4 | No | None | None |
| jSLE110 | 11 | 11.9 | F | 29 | Yes | 1.56 | HCQ, AZT |
| jSLE112 | 11 | 12.4 | F | 4 | No | None | HCQ, AZT |
| jSLE114 | 13 | 16.9 | M | 25 | Yes | 0.25 | HCQ, AZT |
| jSLE117a | 14 | 14.8 | F | 10 | Yes | 0.24 | HCQ, MMF, Dapsone |
| jSLE117b | 15.1 | 0 | Yes | 0.17 | HCQ, MMF, Dapson | ||
| jSLE122 | 15 | 15.2 | F | 9 | No | None | None |
| CIIT1001A | 13 | 15 | F | 2 | No | 0.5 | HCQ, MMF |
| CIIT1008A | 15 | 18 | F | 2 | Yes | 0.2 | HCQ, MMF, Rituximab, Tacrolimus |
| CIIT1003A | 13 | 19 | F | 7 | Yes | 0.13 | HCQ, AZT |
| CIIT0203A | 7 | 16 | F | 22 | Yes | None | None |
| CIIT1020A | 15 | 15.2 | M | 2b | No | 0.5 | HCQ, MMF |
a
Therapeutic regimens including prednisone > 2 mg/kg/day and/or mycophenolatemofetil (MMF), cyclophosphamide (Cyc), or azathioprine (AZT) were considered immunosuppressive.
HCQ = hydroxychloroquine.
b
No SLEDAI available; clinically no disease activity, 2 reflects reduced complement levels.